Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is expected to continue its growth trajectory, with a projected revenue of $350M-$360M in 2026 and a target of $250M in quarterly revenue by 2027. With a strong focus on expanding its product portfolio and targeted marketing efforts, the company is poised for success. The recent J-code approval for one of its key drugs is also expected to drive adoption and contribute to the company's growth. Overall, Harrow's strong financial performance and strategic initiatives make it a promising investment opportunity in the eyecare industry.

Bears say

Harrow is key product IHEEZO launch has not been going as well as initially expected. The revenue recognition shift for the drug may impact its near-term growth, and additional competition in the market from other cyclosporine agents may hinder its long-term success. Additionally, uncertainty around the strength and defense of Harrow's patents presents a potential risk for the company's future revenue streams and financial stability.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.